Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy

Publication

Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy

Journal Paper/Review - Feb 5, 2010

Petrausch U, Renner C, Mischo A, Hany T F, Knuth A, Soyka J D, Veit-Haibach P, Haile Sarah, Samaras P, Schäefer N G

Citation

Petrausch U, Renner C, Mischo A, Hany T, Knuth A, Soyka J, Veit-Haibach P, Haile S, Samaras P, Schäefer N. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol 2010; 21:1694-8.

Type

Journal Paper/Review (English)

Journal

Ann Oncol 2010; 21

Publication Date

Feb 5, 2010

Issn Electronic

1569-8041

Pages

1694-8

Brief description/objective

The purpose of this study was to evaluate the impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) during follow-up of patients with diffuse large B-cell lymphoma (DLBCL) being in complete remission or unconfirmed complete remission after first-line therapy. Patients and methods: DLBCL patients receiving FDG-PET/CT during follow-up were analyzed retrospectively. Confirmatory biopsy was mandatory in cases of suspected disease recurrence.